We are pleased to announce our Bench to Bedside Therapeutic for COVID-19 infections. We intend to bring a very promising drug to market quickly, using a unique pre-clinical and clinical development program.
COVID-19 has exposed unprecedented global risks to humanity. People are suffering severe health problems during and after COVID-19 infection. There are at least 6 different serious medical problems caused by COVID-19 as shown in this slide; COVID-19 exposed a large unmet need in the current therapies, as shown by the failure of Remdesivir to achieve a lowered mortality rate.
Our highly experienced team searched and found the best possible approved drug to overcome the many facets of COVID-19 pathologies, including in the worst case, potential lethality.
We intend to remedy these COVID-19 pathologies & improve patient survival with our drug, PB-004.